Calprotectin Measurement in Rectal Mucus Collected with the OriCol™ Sampling Device: A Method-Comparison Study Against Faecal Calprotectin Reference Tests

Background: Faecal calprotectin is recommended by the UK National Institute of Health and Care Excellence (NICE) HealthTech guidance HTG320 (2013) to distinguish inflammatory bowel disease (IBD) from functional bowel disorders, including irritable bowel syndrome (IBS), when cancer is not suspected, and to monitor IBD activity. Stool collection can limit adherence. Home-based and smartphone-enabled assays partly address this gap, but clinic-acquired sampling could provide results soon after consultation. We compared calprotectin in OriCol™ Sampling Device-collected rectal mucus with matched faecal calprotectin. Methods: Sixty-six adults were prospectively recruited from three NHS gastroenterology clinics. Each provided a clinic-acquired rectal mucus sample and matched stool sample. Calprotectin was measured using two CE-marked ELISAs (IDK® Calprotectin and fCAL®), with laboratory staff blinded to clinical category. The primary endpoint was categorical agreement at the 50 µg/g faecal threshold; secondary analyses included Bland–Altman analysis, Cohen’s κ and patient acceptability. Results: Calprotectin was detected across both assays’ working ranges and correlated positively between matrices. Forty-eight participants were eligible for threshold analysis. Regression-derived rectal mucus equivalents produced positive percent agreement of 79% (95% CI 61–91) for IDK® and 68% (51–82) for fCAL®, and negative percent agreement of 53% (27–79) and 40% (12–74), respectively. Chance-corrected agreement was fair for IDK® (κ 0.32, 95% CI 0.02–0.62) and slight for fCAL® (κ 0.07, 95% CI −0.27–0.41), and Bland–Altman 95% limits of agreement between matrices were wide (spanning roughly two orders of magnitude). Among IBD patients, paired results were above threshold in 93% and 86%, respectively. Of 60 respondents, 96.7% would repeat sampling, 55.6% of those expressing a preference (30 of 54) chose OriCol™, and no OriCol™ Sampling Device-related adverse events occurred. Conclusions: OriCol™ enabled acceptable clinic-based rectal mucus calprotectin measurement with positive correlation to faecal results. Above-threshold agreement was encouraging, but the low negative agreement, the fair-to-slight κ values and the wide between-matrix limits of agreement indicate that rectal mucus calprotectin is not equivalent to faecal calprotectin. Below-threshold agreement, in particular, requires confirmation in larger independent cohorts with pre-specified thresholds before clinical implementation based upon current diagnostic platform threshold.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-12
DOI
https://doi.org/10.3390/diagnostics16223744
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Calprotectin Measurement in Rectal Mucus Collected with the OriCol™ Sampling Device: A Method-Comparison Study Against Faecal Calprotectin Reference Tests

Paul Knight, Daniel G. Wise, Andrew J. Tock, Andrew J. Page et al.
Diagnostics
Inflammatory Bowel Disease
article

Calprotectin Measurement in Rectal Mucus Collected with the OriCol™ Sampling Device: A Method-Comparison Study Against Faecal Calprotectin Reference Tests

Paul Knight, Daniel G. Wise, Andrew J. Tock, Andrew J. Page, Ian R. Daniels, John R McLaughlin, Paul A. Smith
article en

Abstract

Background: Faecal calprotectin is recommended by the UK National Institute of Health and Care Excellence (NICE) HealthTech guidance HTG320 (2013) to distinguish inflammatory bowel disease (IBD) from functional bowel disorders, including irritable bowel syndrome (IBS), when cancer is not suspected, and to monitor IBD activity. Stool collection can limit adherence. Home-based and smartphone-enabled assays partly address this gap, but clinic-acquired sampling could provide results soon after consultation. We compared calprotectin in OriCol™ Sampling Device-collected rectal mucus with matched faecal calprotectin. Methods: Sixty-six adults were prospectively recruited from three NHS gastroenterology clinics. Each provided a clinic-acquired rectal mucus sample and matched stool sample. Calprotectin was measured using two CE-marked ELISAs (IDK® Calprotectin and fCAL®), with laboratory staff blinded to clinical category. The primary endpoint was categorical agreement at the 50 µg/g faecal threshold; secondary analyses included Bland–Altman analysis, Cohen’s κ and patient acceptability. Results: Calprotectin was detected across both assays’ working ranges and correlated positively between matrices. Forty-eight participants were eligible for threshold analysis. Regression-derived rectal mucus equivalents produced positive percent agreement of 79% (95% CI 61–91) for IDK® and 68% (51–82) for fCAL®, and negative percent agreement of 53% (27–79) and 40% (12–74), respectively. Chance-corrected agreement was fair for IDK® (κ 0.32, 95% CI 0.02–0.62) and slight for fCAL® (κ 0.07, 95% CI −0.27–0.41), and Bland–Altman 95% limits of agreement between matrices were wide (spanning roughly two orders of magnitude). Among IBD patients, paired results were above threshold in 93% and 86%, respectively. Of 60 respondents, 96.7% would repeat sampling, 55.6% of those expressing a preference (30 of 54) chose OriCol™, and no OriCol™ Sampling Device-related adverse events occurred. Conclusions: OriCol™ enabled acceptable clinic-based rectal mucus calprotectin measurement with positive correlation to faecal results. Above-threshold agreement was encouraging, but the low negative agreement, the fair-to-slight κ values and the wide between-matrix limits of agreement indicate that rectal mucus calprotectin is not equivalent to faecal calprotectin. Below-threshold agreement, in particular, requires confirmation in larger independent cohorts with pre-specified thresholds before clinical implementation based upon current diagnostic platform threshold.

DiagnosticsVol. 16(22)
Wrightington, Wigan and Leigh NHS Foundation Trust (GB), University of Manchester (GB), Manchester University NHS Foundation Trust (GB), Granta Design (United Kingdom) (GB), Royal Albert Edward Infirmary (GB), Wythenshawe Hospital (GB), Royal Devon University Healthcare NHS Foundation Trust (GB), Northern Care Alliance NHS Foundation Trust (GB)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon